ALAMEDA, Calif. - Penumbra, Inc. (NYSE: NYSE:PEN), a leader in thrombectomy technology, has initiated a share repurchase program, with the Board of Directors authorizing up to $200 million in buybacks on August 5, 2024. This authorization enables the company to repurchase its common stock periodically through various transaction methods, including open market purchases and privately negotiated deals, with the program set to expire on July 31, 2025.
As part of this repurchase plan, Penumbra entered into an accelerated share repurchase agreement (ASR) with JPMorgan Chase (NYSE:JPM) Bank, National Association on August 12, 2024. The agreement stipulates a $100 million buyback of Penumbra's common stock. Penumbra will make an initial payment of $100 million and is slated to receive approximately 474,000 shares on Tuesday.
The final number of shares repurchased will depend on the average daily volume-weighted prices during the ASR term, adjusted for a discount and other terms outlined in the ASR. The completion of this ASR is anticipated by the third quarter of 2024, and the company plans to fund the repurchase with its available cash reserves.
This announcement comes with a cautionary note regarding forward-looking statements, which may be subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from expectations. Factors that may influence outcomes include market conditions, competitive dynamics, product introduction successes, and regulatory changes, among others. The company has detailed these risks in its filings with the Securities and Exchange Commission.
Penumbra, known for its focus on developing innovative medical technologies for the treatment of conditions like ischemic stroke and venous thromboembolism, has a presence in over 100 countries. It aims to support healthcare providers in improving patient outcomes and quality of life through its products, which include computer-assisted vacuum thrombectomy (CAVT) systems designed for the efficient and safe removal of blood clots.
This news is based on a press release statement from Penumbra, Inc. and does not include any promotional content or endorsements of the company's claims.
In other recent news, Penumbra Inc . reported a robust financial performance for the second quarter of 2024. The healthcare company's total revenue reached $299.4 million, a 14.5% increase from the previous year. In particular, U.S. thrombectomy revenue grew by 25% to $153.7 million, and international thrombectomy revenue increased by 26% to $49.8 million.
Despite facing economic challenges in China and delays in Europe, Penumbra is optimistic about future growth, underlined by upcoming product launches and market share gains in thrombectomy.
The company's gross margin expanded to 65.5% on a non-GAAP basis, and operating income stood at $31.7 million, accounting for 10.6% of revenue. Moreover, Penumbra anticipates launching three new CAVT products within the next nine months and expects to achieve more than $20 million in operating savings from the Immersive Healthcare business within the next 12 months.
However, the company has updated its guidance for 2024, forecasting total revenue between $1,180 million to $1,200 million, a reduction of $60 million from previous estimates.
Despite the anticipated reduction in revenue for the second half of the year due to challenges in China and Europe, Penumbra remains focused on innovation and success over financial guidance. The company is confident in resolving its current challenges and expects to benefit from new product launches, setting the stage for future success. These are the recent developments within Penumbra Inc.
InvestingPro Insights
As Penumbra, Inc. (NYSE: PEN) embarks on its share repurchase program, investors may be curious about the company's financial health and market performance. According to recent data provided by InvestingPro, Penumbra is trading at a high earnings multiple, with a P/E ratio of 462.66. However, when adjusted for the last twelve months as of Q2 2024, the P/E ratio stands at a lower but still substantial 76.06.
InvestingPro Tips suggest that Penumbra's cash flows are robust enough to cover interest payments, which is reassuring for investors concerned about the company's financial obligations. Furthermore, Penumbra’s liquid assets exceed its short-term obligations, indicating a solid liquidity position. This financial stability may support the company's decision to initiate a share repurchase program, as it reflects the ability to fund buybacks without compromising operational needs.
Moreover, the company's revenue has shown healthy growth over the last twelve months, with a 20.89% increase as of Q2 2024. This growth is a positive sign for investors, reflecting Penumbra's capacity to expand its market share and enhance profitability.
While Penumbra does not pay a dividend to shareholders, the share repurchase program may offer an alternative form of shareholder return. For investors seeking a deeper analysis, there are additional InvestingPro Tips available, which could provide further insights into Penumbra's valuation and market performance. Visit https://www.investing.com/pro/PEN for more exclusive tips and metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.